News & Announcements
-
Application: FDA Breakthrough Therapy Designation
/**/ RNS Number : 2234H IQ-AI Limited 02 May 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Applies for FDA Breakthrough Therapy Designation May 2, 2025 – Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has today applied to the U.S. Food and Drug Administration for ‘Breakthrough
-
Notice of AGM
/**/ RNS Number : 6338G IQ-AI Limited 29 April 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) AGM Notice IQ-AI is pleased to announce that it will hold its Annual General Meeting (“AGM”) at the offices of IFC5, St Helier, Jersey, JE1 1ST on 22nd May 2025 at 10:00am. The Notice of
-
Publication of Annual Report
/**/ RNS Number : 2817G IQ-AI Limited 25 April 2025 IQ-AI Ltd (“IQ-AI” or “the Company”) Publication of Annual Report The Board of IQ-AI Ltd is pleased to announce the Company’s audited financial statements for the year ended 31 December 2024. The Annual Report will be available on the Company’s corporate website
-
Promising Preliminary Results of Phase 1 Study
/**/ RNS Number : 7655E IQ-AI Limited 11 April 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces Promising Preliminary Results of Phase 1 Study Oral Gallium Maltolate Demonstrates Early Signals of Efficacy IQ-AI is pleased to provide the following update on its wholly-owned subsidiary, Imaging Biometrics LLC. The study on
-
Placing to raise £250,000
/**/ RNS Number : 1361B IQ-AI Limited 18 March 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) Placing to raise £250,000 IQ-AI is pleased to announce that that the Company, through its corporate broker Peterhouse Capital Limited (“Peterhouse”), has conditionally raised gross proceeds of £250,000 via a placing (the “Placing”) of 25,000,000 new